Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia

Cancer Genetics and Cytogenetics

Volumn 192, Issue 1, 2009, Pages 36-39

  Kelly, JoAnn C ^a   Shahbazi, Nasrin ^a   Scheerle, Jay ^a   Jahn, Jennifer ^a   Suchen, Stephany ^a   Christacos, Nicole C ^a   Mowrey, Philip N ^a   Witt, Mary H ^b   Hostetter, Alden ^b   Meloni Ehrig, Aurelia M ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b Rockingham Memorial Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; TRANSCRIPTION FACTOR ETV6;

ABDOMINAL DISCOMFORT; AGED; ARTICLE; CASE REPORT; CHILL; CHROMOSOME 12P; CHROMOSOME 9Q; CHROMOSOME INSERTION; CHRONIC MYELOID LEUKEMIA; DECREASED APPETITE; DRUG RESPONSE; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LOWER ABDOMINAL PAIN; MALAISE; MALE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; RESPIRATORY FAILURE; WEIGHT REDUCTION;

AGED; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 9; FATAL OUTCOME; HUMANS; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MALE; MUTAGENESIS, INSERTIONAL; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES;

ALIAS;

EID: 65749108683     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.02.012     Document Type: Article

References (22)

1. Faderl S., Kantarjian H.M., and Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park) 13 (1999) 169-180 discussion 181, 184
2. Deininger M.W., Goldman J.M., and Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 96 (2000) 3343-3356
3. Johansson B., Fioretos T., and Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107 (2002) 76-94
4. Papadopoulos P., Ridge S.A., Boucher C.A., Stocking C., and Wiedemann L.M. The novel activation of ABL by fusion to an ETS-related gene, TEL. Cancer Res 55 (1995) 34-38
5. Kawamata N., Dashti A., Lu D., Miller B., Koeffler H.P., Schreck R., Moore S., and Ogawa S. Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer 47 (2008) 919-921
6. Andreasson P., Johansson B., Carlsson M., Jarlsfelt I., Fioretos T., Mitelman F., and Höglund M. BRC/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer 20 (1997) 299-304
7. Golub T.R., Goga A., Barker G.F., Afar D.E., McLaughlin J., Bohlander S.K., Rowley J.D., Witte O.N., and Gilliland D.G. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol 16 (1996) 4107-4116
8. Van Limbergen H., Beverloo H.B., van Drunen E., Janssens A., Hählen K., Poppe B., Van Roy N., Marynen P., De Paepe A., Slater R., and Speleman F. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer 30 (2001) 274-282
9. La Starza R., Trubia M., Testoni N., Ottaviani E., Belloni E., Crescenzi B., Martelli M., Flandrin G., Pelicci P.G., and Mecucci C. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 87 (2002) 789-794
10. Lin H., Guo J.Q., Andreeff M., and Arlinghaus R.B. Detection of dual TEL-ABL transcripts and a TEL-ABL protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia 16 (2002) 294-297
11. O'Brien S.G., Vieira S.A., Connors S., Bown N., Chang J., Capdeville R., and Melo J.V. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood 99 (2002) 3465-3467
12. Barbouti A., Ahlgren T., Johansson B., Höglund M., Lassen C., Turesson I., Mitelman F., and Fioretos T. Clinical and genetic studies of ETV6/ABL 1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol 122 (2003) 85-93
13. Wang L.C., Kuo F., Fujiwara Y., Gilliland D.G., Golub T.R., and Orkin S.H. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the ETS-related factor TEL. EMBO J 16 (1997) 4374-4383
14. Wang L.C., Swat W., Fujiwara Y., Davidson J., Visvader J., Kuo F., Alt F.W., Gilliland D.G., Golub T.R., and Orkin S.H. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev 12 (1998) 2392-2402
15. Mitelman F, Johansson B, Mertens F, editors. Mitelman database of chromosome aberrations in cancer [Internet]. Updated Aug. 2008. Accessed Aug. 31, 2008. Available athttp://cgap.nci.nih.gov/Chromosomes/Mitelman.
16. In: Shaffer L.G., and Tommerup N. (Eds). ISCN 2005: an international system for human cytogenetic nomenclature (2005), S. Karger, Basel 2005
17. Secker-Walker L.M., and Craig J.M. Prognostic implications of breakpoint and lineage heterogeneity in Philadelphia-positive acute lymphoblastic leukemia: a review. Leukemia 7 (1993) 147-151
18. Gotoh A., and Broxmeyer H.E. The function of BCR/ABL and related proto-oncogenes. Curr Opin Hematol 4 (1997) 3-11
19. Gesbert F., and Griffin J.D. Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood 96 (2000) 2269-2276
20. Hannemann J.R., McManus D.M., Kabarowski J.H., and Wiedemann L.M. Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol 102 (1998) 475-485
21. Million R.P., Aster J., Gilliland D.G., and Van Etten R.A. The TEL-ABL (ETV6-ABL) tyrosine kinase product of complex (9;12) translocations in human leukemia induces distinct myeloproliferative disease in mice. Blood 99 (2002) 4568-4577
22. Druker B.J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8 4 Suppl (2002) S14-S18